← Back to Search

Other

Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects

Minneapolis, MN
Phase 1
Waitlist Available
Led By Daniel K. Ries, MD
Research Sponsored by Angion Biomedica Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of a single-dose of ANG-3777 in subjects with renal failure receiving maintenance hemodialysis.

See full description

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ANG-3777Experimental Treatment1 Intervention
Administered IV as a single dose over 30 minutes on Day 1, greater than 24 hours before receiving scheduled hemodialysis (HD).

Find a Location

Closest Location:Hennepin County Medical Center (HCMC)· Minneapolis, MN

Who is running the clinical trial?

Angion Biomedica CorpLead Sponsor
11 Previous Clinical Trials
946 Total Patients Enrolled
Nucleus Network LtdOTHER
11 Previous Clinical Trials
506 Total Patients Enrolled
Daniel K. Ries, MDPrincipal InvestigatorNucleus Network Ltd
1 Previous Clinical Trials
16 Total Patients Enrolled
~4 spots leftby Jan 2026